| Segment Reporting |
Note
7 – Segment Reporting
We
manage our 1operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our chief operating
decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus
actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations
and comprehensive loss as consolidated net loss.
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and nine months ended September 30, 2025 and 2024:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Preclinical, clinical trial and other costs |
|
$ |
1,204,017 |
|
|
$ |
1,850,812 |
|
|
$ |
4,543,279 |
|
|
$ |
4,143,813 |
|
| Research and development personnel expense(1) |
|
|
457,629 |
|
|
|
436,713 |
|
|
|
1,153,412 |
|
|
|
1,412,881 |
|
| General and administrative personnel expense(2) |
|
|
855,089 |
|
|
|
493,144 |
|
|
|
2,157,979 |
|
|
|
1,457,941 |
|
| Administrative and facilities expense(3) |
|
|
972,108 |
|
|
|
644,184 |
|
|
|
2,431,946 |
|
|
|
2,301,840 |
|
| Other income, net |
|
|
(52,270 |
) |
|
|
(40,150 |
) |
|
|
(81,720 |
) |
|
|
(195,065 |
) |
| Total |
|
$ |
3,436,573 |
|
|
$ |
3,384,703 |
|
|
$ |
10,204,896 |
|
|
$ |
9,121,410 |
|
| (1) |
Research
and development personnel costs include employee stock-based compensation expense of $110,239 and $54,018 for the three months ended
September 30, 2025 and 2024, respectively, and $165,572 and $130,722 for the nine months ended September 30, 2025 and 2024, respectively. |
| |
|
| (2) |
General
and administrative personnel costs include employee stock-based compensation expense of $192,808 and $53,725 for the three months
ended September 30, 2025 and 2024, respectively, and $438,118 and $132,905 for the nine months ended September 30, 2025 and 2024,
respectively, and are net of reimbursements received from CorLyst, LLC. |
| |
|
| (3) |
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
|